2023
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
Abu-Khalaf M, Alex Hodge K, Hatzis C, Baldelli E, El Gazzah E, Valdes F, Sikov W, Mita M, Denduluri N, Murphy R, Zelterman D, Liotta L, Dunetz B, Dunetz R, Petricoin E, Pierobon M. AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers. Npj Precision Oncology 2023, 7: 18. PMID: 36797347, PMCID: PMC9935518, DOI: 10.1038/s41698-023-00360-5.Peer-Reviewed Original ResearchEndocrine therapyProgressive diseaseCDK4/6 inhibitionImmune cellsTumor epitheliumOpen-label multicenter clinical trialMetastatic breast cancer patientsPI3K/AKT/mTOR activationFirst-line treatmentMetastatic breast cancerBreast cancer patientsAkt/mTOR activationMulticenter clinical trialAkt/mTORMBC patientsCancer patientsPredictive markerClinical trialsDisease progressionBreast cancerTreatment selectionTissue biopsiesPatientsNumber of FDAMTOR activation
2020
CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction.
Abu-Khalaf M, Hatzis C, Hodge K, Valdes F, Sikov W, Mita M, Denduluri N, Awerkamp K, Murphy R, Zelterman D, Dunetz B, Petricoin E, Pierobon M. CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction. Journal Of Clinical Oncology 2020, 38: e13029-e13029. DOI: 10.1200/jco.2020.38.15_suppl.e13029.Peer-Reviewed Original ResearchMetastatic breast cancerBreast cancerCyclin D1CDK 4/6 inhibitorsBaseline tumor tissueClass of drugsAdjuvant settingEndocrine therapyTherapy initiationFrontline therapyInhibitor therapyPFS intervalStudy treatmentPredictive markerDisease progressionClinical trialsOutcome dataTreatment selectionPathway biomarkersBiopsy materialAverage age 62Tumor tissuePatientsFinal analysisTop quartile
2012
The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer
Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP. The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer. PLOS ONE 2012, 7: e37891. PMID: 22662244, PMCID: PMC3360659, DOI: 10.1371/journal.pone.0037891.Peer-Reviewed Original ResearchConceptsPrimary patientsOvarian cancer riskKRAS-variantOvarian cancer diagnosisOvarian cancerPrimary cancerFamily historyCancer diagnosisCancer riskTriple-negative breast cancerAdditional cancer diagnosesDouble primary breastTriple primary cancersPositive family historyAge of diagnosisNegative breast cancerDeleterious BRCA mutationsBreast primaryPathologic diagnosisBRCA mutationsPrimary breastBreast cancerHBOC familiesPatientsHereditary breast
1996
Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation.
Salloum E, Doria R, Schubert W, Zelterman D, Holford T, Roberts K, Farber L, Kiehl R, Cardinale J, Cooper D. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. Journal Of Clinical Oncology 1996, 14: 2435-43. PMID: 8823321, DOI: 10.1200/jco.1996.14.9.2435.Peer-Reviewed Original ResearchConceptsOverall relative riskHodgkin's diseaseRT groupRelative riskSolid tumorsCMT groupRadiation therapyLung cancerBreast cancerEarly-stage Hodgkin's diseaseFull-dose radiation therapyInvolved-field radiationSecond solid tumorsConnecticut Tumor RegistryEarly-stage diseaseLong-term survivorsDifferent therapeutic approachesCases of lungLow-dose radiationSignificant increaseActuarial incidenceMedian followSalvage chemotherapyAdvanced diseaseDurable remissions